Erratum: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development (Cardiovascular Research (2003) 58 (32-45) DOI: 10.1016/S0008-6363(02)00846-5);Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development

Cardiovascular Research

Volumn 58, Issue 1, 2003, Pages 32-45

  Redfern, W S ^a   Carlsson, L ^b   Davis, A S ^a   Lynch, W G ^a   MacKenzie, I ^c   Palethorpe, S ^a   Siegl, P K S ^d   Strang, I ^a   Sullivan, A T ^e   Wallis, R ^f   Camm, A J ^g   Hammond, T G ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c Department of Environmental Air Quality   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiarrhythmic agents; Arrhythmia (mechanisms); Ion channels; K channel; Long QT syndrome; Repolarization; Sudden death; Ventricular arrhythmias

Indexed keywords

ALMOKALANT; AMIODARONE; APRINDINE; ASTEMIZOLE; AZIMILIDE; CISAPRIDE; DOFETILIDE; DOMPERIDONE; ERYTHROMYCIN; FLECAINIDE; GREPAFLOXACIN; HALOPERIDOL; IBUTILIDE; ION; ION CHANNEL; MIBEFRADIL; NIFEDIPINE; PIMOZIDE; POTASSIUM CHANNEL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SEMATILIDE; SERTINDOLE; SOTALOL; SPARFLOXACIN; TEDISAMIL; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL;

ACTION POTENTIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG SAFETY; DRUG USE; HEART ELECTROPHYSIOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PUBLISHING; QT INTERVAL; REPOLARIZATION; REVIEW; RISK ASSESSMENT; TORSADE DES POINTES;

EID: 0344492207     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.04.016     Document Type: Erratum

References (75)

1. Raehl C.L., Patel A.K., LeRoy M. Drug-induced torsade de pointes. Clin Pharm. 4:1985;675-690.
2. Woosley R.L. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 36:1996;233-252.
3. Yap Y.G., Camm A.J. The current cardiac safety situation with antihistamines. Clin Exp Allergy. 29:(Suppl 1):1999;15-24.
4. Glassman A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 158:2001;1774-1782.
5. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J. 3:(Suppl K):2001;K70-K80.
6. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
7. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Cardiovasc Res. 47:2000;219-233. published simultaneously in Eur Heart J 2000;21:1216-1231.
8. El-Sherif N., Turitto G. The long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 22:1999;91-110.
9. De Ponti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 56:2000;1-18.
10. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol. 57:2001;185-209.
11. Catterall W.A., Chandy K.G., Gutman G.A. The IUPHAR compendium of voltage-gated ion channels. 2002;128-129 IUPHAR Media, Leeds.
12. Committee for Proprietary Medicinal Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96, 1997.
13. Davis A.S. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol. 17:1998;677-680.
14. Cavero I., Mestre M., Guillon J.-M., Heuillet E., Roach A. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Safety. 21:(Suppl 1):2000;19-31. and panel discussion, pp. 81-87.
15. Carlsson L. Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J. 3:(Suppl K):2001;K114-K120.
16. Hammond T.G., Carlsson L., Davis A.S., et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res. 49:2001;741-750.
17. SoRelle R. Withdrawal of Posicor from market. Circulation. 98:1998;831-832.
18. Gläser S., Steinbach M., Opitz C., Wruck U., Kleber F.X. Torsades de Pointes caused by mibefradil. Eur J Heart Failure. 3:2001;627-630.
19. ©, The Pharmaceutical Press, 2002.
20. Gilman A.G., et al. Goodman and Gilman's 'The Pharmacological Basis of Therapeutics'. 8th ed. 1990;1655-1715 Pergamon Press, New York.
21. Antzelevitch C., Shimizu W., Yan G.X., et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 10:1999;1124-1152.
22. Vos M.A., van Opstal J.M., Leunissen J.D.M., Verduyn S.C. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther. 92:2001;109-122.
23. Kang J., Chen X.-L., Wang L., Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther. 299:2001;290-296.
24. Coker S.J., Batey A.J., Lightbown I.D., Díaz M.E., Eisner D.A. Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes. Br J Pharmacol. 129:2000;323-330.
25. Roden D.M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res. 50:2001;224-231.
26. Roden D.M. Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol. 21:1998;1029-1034.
27. Krikler D.M., Curry P.V.L. Torsade de pointes, an atypical ventricular tachycardia. Br Heart J. 38:1976;117-120.
28. Kodama I., Kamiya K., Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 35:1997;13-29.
29. Ks, in guinea-pig ventricular myocytes. Br J Pharmacol. 128:1999;1733-1738.
30. Ks. Thérapie. 55:2000;195-202.
31. Hollingshead L.M., Faulds D., Fitton A. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs. 44:1992;835-857.
32. Nadamenee K., Singh B.N. Control of cardiac arrhythmias by calcium antagonists. Ann NY Acad Sci. 522:1988;536-552.
33. 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol. 119:1996;187-188.
34. Williams A., Redfern W.S., Day A., Gracie K.J., Patmore L. Prolongation of QTc interval by ketoconazole in conscious guinea-pigs implanted with ECG telemetry transducers. Br J Pharmacol. 119:1996;356P. (Abstract).
35. Gras J., Llenas J. Effects of H1 antihistamines on animal models of QTc prolongation. Drug Safety. 21:(Suppl 1):1999;39-44.
36. McFadden E.P., Clarke J.G., Davies G.J., et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. New Engl J Med. 324:1991;648-654.
37. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifoloxacin, and moxifloxacin. Pharmacotherapy. 21:2001;1468-1472.
38. Furuhata K., Hayakawa H., Soumi K., et al. Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration. Biol Pharm Bull. 21:1998;456-460.
39. Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol. 86:1990;684-686.
40. Pratt C.M., Hertz R.P., Ellis B.E., et al. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol. 73:1994;346-352.
41. Zareba W., Moss A.J., Rosero S.Z., et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol. 80:1997;1168-1173.
42. Grayson H.A., Kennedy J.D. Torsades de pointes and nifedipine. Ann Intern Med. 97:1982;144.
43. Krikler D.M., Rowland E. Torsade de pointes and nifedipine. Ann Intern Med. 97:1982;618-619.
44. Grayson H.A., Kennedy J.D. Nifedipine and torsades de pointes. Ann Intern Med. 99:1983;281-282.
45. Peters F.P.J., de Zwaan C., Kho L. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension. Arch Intern Med. 157:1997;2665-2666.
46. Daleau P., Lessard E., Groleau M.-F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 91:1995;3010-3016.
47. Benet L.Z., Hoener B.-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 71:2002;115-121.
48. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety. 25:2002;263-286.
49. Sosunov E., Anyukhovsky E.P., Rosen M.R. Effects of quinidine on repolarisation in canine epicardium, midmyocardium, and endocardium. Circulation. 96:1997;4011-4018.
50. Nattel S., Singh B.N. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol. 84:1999;11R-19R.
51. Kr: the hERG channel. J Mol Cell Cardiol. 33:2001;835-849.
52. + channel. Circ Res. 78:1996;499-503.
53. + channels: friend and foe. Trends Pharmacol Sci. 22:2001;240-246.
54. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential prolongation is antiarrhythmic. Circulation. 103:2001;2004-2013.
55. Antzelevitch C., Sicouri S., Litovsky S.H., et al. Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ Res. 69:1991;1427-1449.
56. Antzelevitch C. Heterogeneity of cellular repolarization in LQTS: the role of M cells. Eur Heart J. 3:(Suppl K):2001;K2-K16.
57. Zhang M.-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem. 4:1997;171-184.
58. 1 receptor blocker cetirizine compared to other second-generation antihistamines. Mol Pharmacol. 54:1998;113-121.
59. Segarra V., López M., Ryder H., Palacios J.M., Roberts D.J. Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine. Drug Safety. 21:(Suppl 1):1999;45-61.
60. Morgan T.K., Sullivan M.E. An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. Ellis G.P., Luscombe D.K. Progress in medicinal chemistry. 1992;65-108 Elsevier, Amsterdam.
61. Mitcheson J.S., Chen J., Lin M., Culbertson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci. 97:2000;12329-12333.
62. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether a-go-go-related gene potassium channel. J Pharmacol Exp Ther. 301:2002;427-434.
63. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today. 2:1999;270-280.
64. Champeroux P., Martel E., Vannier C., et al. The preclinical assessment of the risk for QT interval prolongation. Thérapie. 55:2000;101-109.
65. Cavero I., Mestre M., Guillon J.-M., Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother. 1:2000;947-973.
66. Malik M., Camm A.J. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Safety. 24:2001;323-351.
67. Gralinski M.R. The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. J Pharmacol Toxicol Methods. 43:2000;91-99.
68. Shah R.R. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol. 16:2002;119-124.
69. Shah R.R. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol. 16:2002;147-156.
70. Lu H.R., Mariën R., Saels A., De Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibres. J Cardiovasc Electrophysiol. 12:2002;93-102.
71. Puglisi J.L., Bers D.M. LabHEART: an interactive computer model of rabbit ventricular myocyte ion channels and Ca transport. Am J Physiol Cell Physiol. 281:2001;C2049-C2060.
72. Webster R., Leishman D., Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev. 5:2002;116-126.
73. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Couer Vaiss. 59:1966;263-272.
74. MacWilliam J.A. Some applications of physiology to medicine: II. Ventricular fibrillation and sudden death. Br Med J. 2:1923;215-219.
75. Hollister L.E., Kosek J.C. Sudden death during treatment with phenothiazine derivatives. J Am Med Assoc. 192:1965;93-96.